# Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

> **NCT01065051** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 1 (actual)

## Conditions studied

- Hypertension, Pulmonary
- Ventricular Dysfunction, Left

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01065051
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065051, "Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01065051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*